Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma
Matteo Costacurta,
Stephin J Vervoort,
Simon J Hogg,
Benjamin P Martin,
Ricky W Johnstone,
Jake Shortt
Affiliations
Matteo Costacurta
Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Stephin J Vervoort
Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Simon J Hogg
Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Benjamin P Martin
Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Ricky W Johnstone
Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne
Jake Shortt
Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville; Monash Haematology, Monash Health, Clayton; Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Monash University, Clayton